As of Jul 22
| +0.03 / +1.89%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 1.86, with a high estimate of 2.18 and a low estimate of 1.55. The median estimate represents a +15.09% increase from the last price of 1.62.
The current consensus among 3 polled investment analysts is to Hold stock in Transition Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.